|Preferred IUPAC name
Irgasan DP 300
3D model (JSmol)
CompTox Dashboard (EPA)
|Molar mass||289.54 g·mol−1|
|Melting point||55–57 °C (131–135 °F; 328–330 K)|
|Boiling point||120 °C (248 °F; 393 K)|
|D08AE04 (WHO) D09AA06 (WHO) (medicated dressing)|
|Safety data sheet||MSDS|
|NFPA 704 (fire diamond)|
|Flash point||162.2 °C (324.0 °F; 435.3 K)|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Triclosan (sometimes abbreviated as TCS) is an antibacterial and antifungal agent present in some consumer products, including toothpaste, soaps, detergents, toys, and surgical cleaning treatments. It is similar in its uses and mechanism of action to triclocarban. Its efficacy as an antimicrobial agent, the risk of antimicrobial resistance, and its possible role in disrupted hormonal development remains controversial. Additional research seeks to understand its potential effects on organisms and environmental health.
Triclosan was developed in the 1960s. Finding no benefit for consumers and given the risk of antibiotic resistance, in December 2017, the FDA announced that "consumer antiseptic washes" containing triclosan or 23 other ingredients marketed as antimicrobials were prohibited without pre-market approval. The FDA did find that triclosan in Colgate Total toothpaste helped prevent gingivitis.
Triclosan was used as a hospital scrub in the 1970s. Since then, it has expanded commercially and is now a common ingredient in soaps (0.10–1.00%), shampoos, deodorants, toothpastes, mouthwashes, cleaning supplies, and pesticides. It is part of consumer products, including kitchen utensils, toys, bedding, socks, and trash bags.
As of 2017, there were five registrations[further explanation needed] for triclosan with the EPA. The antimicrobial active ingredient is added to a variety of products where it acts to slow or stop the growth of bacteria, fungi, and mildew. In commercial, institutional, and industrial equipment uses, triclosan is incorporated in conveyor belts, fire hoses, dye bath vats, or ice-making equipment as an antimicrobial. Triclosan may be directly applied to commercial HVAC coils, where it prevents microbial growth that contributes to product degradation.
In healthcare, triclosan is used in surgical scrubs and hand washes. Use in surgical units is effective with a minimum contact time of approximately two minutes. More recently,[when?] showering with 2% triclosan has become a recommended regimen in surgical units for the decolonization of patients whose skin carries methicillin-resistant Staphylococcus aureus (MRSA). Two small uncontrolled case studies reported the use of triclosan correlated with reduction in MRSA infections.
Triclosan is also used in the coatings for some surgical sutures. There is good evidence these triclosan coated sutures reduce the risk of surgical site infection. The World Health Organization, the American College of Surgeons and the Surgical Infection Society point out the benefit of triclosan-coated sutures in reducing the risk for surgical site infection.
Triclosan has been employed as a selective agent in molecular cloning. A bacterial host transformed by a plasmid harboring a triclosan-resistant mutant FabI gene (mFabI) as a selectable marker can grow in presence of high dose of triclosan in growth media.
In surgery, triclosan coated sutures reduce the risk of surgical site infection. Some studies suggest that antimicrobial hand soaps containing triclosan provide a slightly greater bacterial reduction on the hands compared to plain soap. As of 2013[update], the US FDA had found clear benefit to health for some consumer products containing triclosan, but not in others; for example the FDA had no evidence that triclosan in antibacterial soaps and body washes provides any benefit over washing with regular soap and water.
A Cochrane review of 30 studies concluded that triclosan/copolymer-containing toothpastes produced a 22% reduction in both dental plaque and gingival inflammation when compared with fluoride toothpastes without triclosan/copolymer. There was weak evidence of a reduction in tooth cavities, and no evidence of reduction in periodontitis.
A study of triclosan toothpastes did not find any evidence that it causes an increase in serious adverse cardiac events such as heart attacks.
A study by Colgate-Palmolive found a significant reduction in gingivitis, bleeding, and plaque with the use of triclosan-containing toothpaste, but an independent review of the Cochrane group suggests that while the reduction in gingivitis, bleeding, and plaque may be statistically significant, it may not be beneficial enough to yield clinical significance.[clarification needed]
Chemical structure and properties
This organic compound is a white powdered solid with a slight aromatic, phenolic odor. Categorized as a polychloro phenoxy phenol, triclosan is a chlorinated aromatic compound that has functional groups representative of both ethers and phenols. Phenols often demonstrate antibacterial properties. Triclosan is soluble in ethanol, methanol, diethyl ether, and strongly basic solutions such as a 1M sodium hydroxide solution, but only slightly soluble in water. Triclosan can be synthesized from 2,4-dichlorophenol.
The United States Pharmacopeia formulary has published a monograph for triclosan that sets purity standards.
Mechanism of action
At high concentrations, triclosan acts as a biocide with multiple cytoplasmic and membrane targets. However, at the lower concentrations seen in commercial products, triclosan appears bacteriostatic, and it targets bacteria primarily by inhibiting fatty acid synthesis.
Triclosan binds to bacterial enoyl-acyl carrier protein reductase (ENR) enzyme, which is encoded by the gene fabI. This binding increases the enzyme's affinity for nicotinamide adenine dinucleotide (NAD+). This results in the formation of a stable, ternary complex of ENR-NAD+-triclosan, which is unable to participate in fatty acid synthesis. Fatty acids are necessary for building and reproducing cell membranes. Humans do not have an ENR enzyme and thus are not affected by this mode of action.
Triclosan has been found to be a weak endocrine disruptor, though the relevance of this to humans is uncertain. The compound has been found to bind with low affinity to both the androgen receptor and the estrogen receptor, where both agonistic and antagonistic responses have been observed.
Efflux pump inducer
Humans are exposed to triclosan through skin absorption when washing hands or in the shower, brushing teeth, using mouthwash or doing dishes, and through ingestion when swallowed. When triclosan is released into the environment, additional exposure to the chemical is possible through ingesting plants grown in soil treated with sewage sludge, or eating fish exposed to it.
An article from the American Society of Agronomy refers to a study done by Monica Mendez et al., in which the researchers irrigated plants with water containing triclosan and months later found it in all edible parts of tomato and onion plants. Triclosan is found to kill a wide spectrum of bacteria, and the researchers are also concerned about the effect it has on the beneficial bacteria in soil.
Distribution, metabolism, and elimination
Once absorbed, triclosan is metabolized by humans primarily through conjugation reactions into glucuronide and sulfate conjugates that are excreted in feces and urine. Pharmacokinetic studies demonstrate that triclosan sulfate and glucuronide may be formed in the liver at approximately equal rates at the environmentally relevant concentration of 1 to 5 microMolar. When concentrations of triclosan are below 1 microMolar, sulfonation is expected to be the major metabolic pathway for elimination.
Because of potential health concerns, due to the possibility of antimicrobial resistance, endocrine disruption and other issues as listed below, triclosan has been designated as a "contaminant of emerging concern (CEC)", meaning it is under investigation for public health risk. "Emerging contaminants" can be broadly defined as any synthetic or naturally occurring chemical or any microorganism that is not commonly monitored in the environment but has the potential to enter the environment and cause known or suspected adverse ecological or human health effects. Triclosan is thought to accumulate in wastewater and return to drinking water, thus propagating a buildup that could cause increasing effects with ongoing use.
In the United States, after a decades-long review of the potential health issues from this contaminant of emerging concern, the FDA ruled on September 6, 2016, that 19 active ingredients including triclosan are not generally recognized as safe and effective (GRAS/GRAE). (See policy section below).
Triclosan has been associated with a higher risk of food allergy. This may be because exposure to bacteria reduces allergies, as predicted by the hygiene hypothesis, and not caused by toxicology of triclosan itself. This effect may also occur with chlorhexidine gluconate and PCMX, among other antibacterial agents. Other studies have linked triclosan to allergic contact dermatitis in some individuals. Additionally, triclosan concentrations have been associated with allergic sensitization, especially inhalant and seasonal allergens, rather than food allergens.
Triclosan can react with the free chlorine in chlorinated tap water to produce lesser amounts of other compounds, such as 2,4-dichlorophenol. Some of these intermediates convert into dioxins upon exposure to UV radiation (from the sun or other sources). The dioxins that can form from triclosan are not considered to be congeners of toxicologic concern for mammals, birds and fish.
Concerns on the health effects of triclosan have been raised after it was detected in human breast milk, blood, and urine samples. Studies on rats have shown that triclosan exposure modulates estrogen-dependent responses. There have been many studies performed over the years both in vivo and in vitro, in male and female fish and rats and they all support the conclusion that triclosan possesses (anti)estrogenic and (anti)androgenic properties depending on species, tissues, and cell types. In a 2017 study on 537 pregnant women in China, prenatal triclosan exposure was associated with increased cord testosterone levels in the infants.
Triclosan (TCS) was patented in 1964 by Swiss company Ciba-Geigy. The earliest known safety testing began in 1968. It was introduced the next year, mainly for use in hospitals, and was in worldwide production and use by the early 1970s.
In 1997 Ciba-Geigy merged with another Swiss company, Sandoz, to form Novartis. During the merger, Ciba-Geigy's chemical business was spun off to become Ciba Specialty Chemicals, which was acquired in 2008 by chemical giant BASF. BASF currently manufactures TCS under the brand name Irgasan DP300.
Treatment and disposal
Exposure to triclosan in personal product use is relatively short. Upon disposal, triclosan is sent to municipal sewage treatment plants, where, in the United States, about 97–98% of triclosan is removed. Studies show that substantial quantities of triclosan (170,000–970,000 kg/yr) can escape from wastewater treatment plants and damage algae on surface waters. In a study on effluent from wastewater treatment facilities, approximately 75% of triclocarban was present in sewage sludge. This poses a potential environmental and ecological hazard, particularly for aquatic systems. The volume of triclosan, in the United States, re-entering the environment in sewage sludge after initial successful capture from wastewater is 44,000 ± 60,000 kg/yr. Triclosan can attach to other substances suspended in aquatic environments, which potentially endangers marine organisms and may lead to further bioaccumulation. Ozone is considered to be an effective tool for removing triclosan during sewage treatment. As little triclosan is released through plastic and textile household consumer products, these are not considered to be major sources of triclosan contamination.
During wastewater treatment, a portion of triclosan is degraded, while the remaining adsorbs to sewage sludge or exits the plant as effluent. A mass balance in Athens (Greece) Sewage Treatment Plant (2013) showed that 43% of triclosan is accumulated to the primary and secondary sludge, 45% is lost due to degradation while the rest 12% is discharged to the environment via the secondary treated wastewater. In the environment, triclosan may be degraded by microorganisms or react with sunlight, forming other compounds, which include chlorophenols and dioxins.
During 1999 to 2000, US Geological Survey detected TCS in 57.6% of streams and rivers sampled.
While studies using semi-permeable membrane devices have found that triclosan does not strongly bioaccumulate, methyl-triclosan is comparatively more stable and lipophilic and thus poses a higher risk of bioaccumulation. The ability of triclosan to bioaccumulate is affected by its ionization state in different environmental conditions.
Triclosan is toxic to aquatic bacteria at levels found in the environment. It is highly toxic to various types of algae and has the potential to affect the structure of algal communities, particularly immediately downstream of effluents from wastewater treatment facilities that treat household wastewaters. Triclosan has been observed in multiple organisms, including algae, aquatic blackworms, fish, and dolphins. It has also been found in land animals including earthworms and species higher up the food chain. In toxicity experiments with Vibrio fischeri marine bacterium, an EC50 value of TCS equal to 0.22 mg/L has been determined. Few data is available for the long-term toxicity of TCS to algae, daphnids and fish, while enough data is available for its acute toxicity on these groups of organisms.
A 2017 study that used risk quotient (RQ) methodology and evaluated the ecological threat due to the discharge of wastewater containing TCS in European rivers, reported that the probability that RQ values exceeds 1 ranged from 0.2% (for rivers with dilution factor of 1000) to 45% (for rivers with dilution factor 2).
Triclosan favors anaerobic conditions which is typical in soil and sediment. The antimicrobial properties of Triclosan are resistant to anaerobic degradation which is the main contributor to its persistence in the environment.
Concern pertains to the potential for cross-resistance (or co-resistance) to other antimicrobials. Numerous studies have been performed and there have been results indicating that the use of biocidal agents, such as triclosan, can cause cross-resistance. A study done in wide range of bacteria and different classes of antibiotics showed that Pseudomonas aeruginosa and Stenotrophomonas maltophilia, already resistant to triclosan, had increased resistance against antibiotics tetracycline and norfloxacin when exposed to triclosan. Results from a study published in The American Journal of Infection Control showed that exposure to triclosan was associated with a high risk of developing resistance and cross-resistance in Staphylococcus aureus and Escherichia coli. This was not observed with exposure to chlorhexidine or a hydrogen peroxide-based agent (during the conditions in said study).
A comprehensive analysis in 2007 from the University of Michigan School of Public Health indicated that plain soaps are just as effective as consumer-grade antibacterial soaps with triclosan in preventing illness and removing bacteria from the hands.
In the US, triclosan is regulated as a pesticide by EPA and as a drug by FDA. EPA generally regulates uses on solid surfaces, and FDA regulations cover uses in personal care products.
In 1974, the US FDA began the drug review monograph process for "over-the-counter (OTC) topical antimicrobial products," including triclosan and triclocarban. The advisory panel first met on June 29, 1972, and the agency published its proposed rule on Sept 13, 1974. The initial rule applied to, “OTC products containing antimicrobial ingredients for topical human use, which includes soaps, surgical scrubs, skin washes, skin cleansers, first aid preparations and additional products defined by the panel.” The proposed rule lists dozens of products that were already on the market at the time and the firms that produced them.
In 1978 FDA published a tentative final monograph (TFM) for topical antimicrobial products. The record was re-opened in March 1979 to take into account six comments the agency received during the period for submitting objections to the TFM, including new data submitted by Procter & Gamble on the safety and effectiveness of triclocarban and by Ciba-Geigy on the proliferation of use of triclosan. The document states that, “significant amounts of new and previously unconsidered data were submitted with each of the above petitions.” It was re-opened again in October of that year to permit interested persons to submit further data establishing conditions for the safety, effectiveness and labeling of over-the-counter topical antimicrobial products for human use.
The next document issued was a proposed rule dated June 17, 1994, which states, “FDA is issuing a notice of proposed rulemaking in the form of an amended tentative final monograph that would establish conditions under which OTC topical health-care antiseptic drug products are generally recognized as safe and effective and not misbranded. FDA is issuing this notice of proposed rulemaking on topical antimicrobial drug products after considering the public comments on that notice and other information in the administrative record for this rulemaking. FDA is also requesting data and information concerning the safety and effectiveness of topical antimicrobials for use as hand sanitizers or dips.” In the 1994 update to the rule, TCS was effectively removed from the drug category which made it available for use in consumer products.
In 2010, the Natural Resources Defense Council forced the FDA to review triclosan after suing the agency for its inaction. Because the FDA prohibited hexachlorophene, a compound similar to triclosan, Halden and others argued that the FDA should also ban triclosan. On December 17, 2013, the FDA issued a draft rule revoking the generally recognized as safe status of triclosan as an ingredient in hand wash products, citing the need for additional studies of its potential endrocrine and developmental effects; impact on bacterial resistance; and carcinogenic potential.
On September 6, 2016, 44 years after its initial proposed rule, FDA issued a final rule establishing that 19 active ingredients, including triclosan and triclocarban, used in over-the-counter (OTC) consumer antiseptic products intended for use with water (aka consumer antiseptic washes) are not generally recognized as safe and effective (GRAS/GRAE) and are misbranded, and are new drugs for which approved applications under section 505 of the FD&C Act are required for marketing. Companies have one year to reformulate products without these ingredients, take them off the market or submit a New Drug Application (NDA) for the products. The 19 ingredients are:
- Iodine complex (ammonium ether sulfate and polyoxyethylene sorbitan monolaurate)
- Iodine complex (phosphate ester of alkylaryloxy polyethylene glycol)
- Methylbenzethonium chloride
- Nonylphenoxypoly (ethyleneoxy) ethanoliodine
- Phenol (greater than 1.5 percent)
- Phenol (less than 1.5 percent)
- Poloxamer-iodine complex
- Povidone-iodine 5 to 10 percent
- Secondary amyltricresols
- Sodium oxychlorosene
- Triple dye
- Undecoylium chloride iodine complex
In 2015 and 2016 FDA also issued proposed rules to amend the 1994 TFM regarding the safety and effectiveness of OTC health care antiseptics and OTC consumer antiseptic rubs.
The state of Minnesota took action against triclosan in advance of a federal rule. In May 2014, the governor signed a bill banning triclosan-containing products in the state. A CNN article quotes the new law, "In order to prevent the spread of infectious disease and avoidable infections and to promote best practices in sanitation, no person shall offer for retail sale in Minnesota any cleaning product that contains triclosan and is used by consumers for sanitizing or hand and body cleansing.” The law goes into effect on Jan 1 2017. The exceptions to this rule are individual products that have received approval from the US Food and Drug Administration for consumer use.
In light of mounting evidence on the human health and ecotoxic effects of triclosan, some companies reformulated to remove it in advance of regulation: Colgate-Palmolive removed it from Palmolive Dish Soap and Softsoap in 2011 (but it remained in Colgate Total toothpaste until late 2018 or early 2019); Johnson & Johnson removed it from baby products in 2012 and all products in 2015; Procter & Gamble from all products in 2014; In 2014 it was removed from Clearasil and Avon began phasing it out; and Unilever removed it from skin care and cleansing products in 2015, and says oral care by 2017.
In Canada, triclosan is allowed in cosmetics, though FDA's recent announcement has prompted Health Canada spokeswoman Maryse Durette to state in an e-mail to Toronto newspaper The Globe and Mail that, “the government will publish a final assessment of the safety of triclosan ‘in the near future’ and take further action ‘if warranted.’” Health Canada maintains a Cosmetic Ingredient Hotlist, including hundreds of chemicals that are not allowed or whose use is restricted in cosmetics. The list states that triclosan is currently allowed in cosmetics up to 0.3%, and 0.03% in mouthwashes and other oral products with required warnings to avoid swallowing and not for use in children under the age of 12.
Triclosan was not approved by the European Commission as an active substance for use in biocidal products for product-type 1 in January 2016. In the United States, manufacturers of products containing triclosan must indicate its presence on the label. In Europe, triclosan is regulated as a cosmetic preservative and must be listed on the label. Usage of triclosan in cosmetic products was restricted by the EU commission in 2014.
- Boyce, JM; Pittet, D; Healthcare Infection Control Practices Advisory, Committee.; HICPAC/SHEA/APIC/IDSA Hand Hygiene Task, Force. (25 October 2002). "Guideline for Hand Hygiene in Health-Care Settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America". MMWR. Recommendations and Reports. 51 (RR-16): 1–45, quiz CE1–4. PMID 12418624.
- "5 Things to Know About Triclosan". U.S. Food and Drug Administration. 16 May 2019. Retrieved 12 September 2019.
- Coia, J.E.; Duckworth, G.J.; Edwards, D.I.; Farrington, M.; Fry, C.; Humphreys, H.; Mallaghan, C.; Tucker, D.R.; Joint Working Party of the British Society of Antimicrobial Chemotherapy; Hospital Infection, Society; Infection Control Nurses Association (2006). "Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities". Journal of Hospital Infection. 63: S1–44. doi:10.1016/j.jhin.2006.01.001. PMID 16581155.
- Thompson, A.; Griffin, P.; Stuetz, R.; Cartmell, E. (2005). "The Fate and Removal of Triclosan during Wastewater Treatment". Water Environment Research. 77 (1): 63–67. doi:10.2175/106143005X41636. JSTOR 25045839. PMID 15765937.
- Record in the Household Products Database of NLM
- National Pesticide Information Retrieval System. Retrieved from http://ppis.ceris.purdue.edu/, http://ppis.ceris.purdue.edu/chemical2.aspx
- EPA Triclosan Facts. EPA Web Site. Retrieved May 3, 2017, https://archive.epa.gov/pesticides/reregistration/web/html/triclosan_fs.html
- Finley, Cynthia. (May 21, 2014). Washing Away Triclosan with Legislation and Regulation. National Association of Clean Water Agencies website. Retrieved from http://blog.nacwa.org/washing-away-triclosan-with-legislation-and-regulation/
- Halden, p. 3603.
- Food and Drug Administration (17 June 1994). "Federal Register Notice: Tentative Final Monograph for OTC Healthcare Antiseptic Drug Products" (PDF).
- Brady, L.M.; Thomson, M; Palmer, M.A.; Harkness, J. L. (1990). "Successful control of endemic MRSA in a cardiothoracic surgical unit". The Medical Journal of Australia. 152 (5): 240–45. doi:10.5694/j.1326-5377.1990.tb120917.x. PMID 2255283.
- Zafar, A.B.; Butler, R.C.; Reese, D.J.; Gaydos, L.A.; Mennonna, P.A. (1995). "Use of 0.3% triclosan (Bacti-Stat) to eradicate an outbreak of methicillin-resistant Staphylococcus aureus in a neonatal nursery". American Journal of Infection Control. 23 (3): 200–08. doi:10.1016/0196-6553(95)90042-X. PMID 7677266.
- Tobias, Karen M.; Johnston, Spencer A. (2013-12-26). Veterinary Surgery: Small Animal: 2-Volume Set. Elsevier Health Sciences. p. 190. ISBN 9780323263375. Retrieved 26 January 2016.
Triclosan is a commonly used antibiotic coating
- Singer, Adam J.; Hollander, Judd E.; Blumm, Robert M. (2010). Skin and Soft Tissue Injuries and Infections: A Practical Evidence Based Guide. PMPH-USA. p. 95. ISBN 9781607950295. Retrieved 26 January 2016.
Examples of antibacterial sutures that are coated with the antibacterial agent triclosan include... In many institutions these have replaced the comparable non-antibacterial sutures.
- Wang, Z.X.; Jiang, C.P.; Cao, Y.; Ding, Y.T. (March 2013). "Systematic review and meta-analysis of triclosan-coated sutures for the prevention of surgical-site infection". British Journal of Surgery. 100 (4): 465–73. doi:10.1002/bjs.9062. PMID 23338685. S2CID 311834.
- Renko, M; Paalanne, N; Tapiainen, T; Hinkkainen, M; Pokka, T; Kinnula, S; Sinikumpu, JJ; Uhari, M; Serlo, W (January 2017). "Triclosan-containing sutures versus ordinary sutures for reducing surgical site infections in children: a double-blind, randomised controlled trial". The Lancet. Infectious Diseases. 17 (1): 50–57. doi:10.1016/S1473-3099(16)30373-5. PMID 27658562.
- "The Centers for Disease Control and Prevention updated guideline now include a recommendation for Triclosan-Coated Sutures | Ethicon". www.ethicon.com. Ethicon.
- Berríos-Torres, Sandra I.; Umscheid, Craig A.; Bratzler, Dale W.; Leas, Brian; Stone, Erin C.; Kelz, Rachel R.; Reinke, Caroline E.; Morgan, Sherry; Solomkin, Joseph S.; Mazuski, John E.; Dellinger, E. Patchen; Itani, Kamal M. F.; Berbari, Elie F.; Segreti, John; Parvizi, Javad; Blanchard, Joan; Allen, George; Kluytmans, Jan A.J.W.; Donlan, Rodney; Schecter, William P. (1 August 2017). "Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017". JAMA Surgery. 152 (8): 784–91. doi:10.1001/jamasurg.2017.0904. PMID 28467526.
- Jang, Chuan-Wei; Magnuson, Terry (2013). "A Novel Selection Marker for Efficient DNA Cloning and Recombineering in E. Coli". PLOS ONE. 8 (2): e57075. Bibcode:2013PLoSO...857075J. doi:10.1371/journal.pone.0057075. PMC 3577784. PMID 23437314.
- Montville, Rebecca; Schaffner, Donald W. (2011). "A Meta-Analysis of the Published Literature on the Effectiveness of Antimicrobial Soaps". Journal of Food Protection. 74 (11): 1875–82. doi:10.4315/0362-028X.JFP-11-122. PMID 22054188.
- "Triclosan: What Consumers Should Know". FDA. 2013-12-16. Retrieved 2014-07-15.
- Riley, P; Lamont, T (2013). "Triclosan/copolymer containing toothpastes for oral health". Reviews. 12 (12): CD010514. doi:10.1002/14651858.CD010514.pub2. PMC 6775959. PMID 24310847.
- Cullinan, Mary P.; Palmer, Janet E.; Carle, Anne D.; West, Malcolm J.; Westerman, Bill; Seymour, Gregory J. (2015-03-01). "The influence of a triclosan toothpaste on adverse events in patients with cardiovascular disease over 5-years". The Science of the Total Environment. 508: 546–52. Bibcode:2015ScTEn.508..546C. doi:10.1016/j.scitotenv.2014.11.052. ISSN 1879-1026. PMID 25442641.
- Rover, Jo-Ann; Leu-Wai-See, Petal (2014-06-01). "Role of Colgate Total toothpaste in helping control plaque and gingivitis". American Journal of Dentistry. 27 (3): 167–70. ISSN 0894-8275. PMID 25208366.
- Kraglund, Ferne (2014-03-01). "Triclosan produces statistically significant reduction in plaque, gingivitis and caries but not clinically important benefit". Evidence-Based Dentistry. 15 (1): 6–7. doi:10.1038/sj.ebd.6400980. ISSN 1476-5446. PMID 24763165. S2CID 34379017.
- "Table 3: Solubility of triclosan in selected solvents and chemicals - Figures and Tables". copublications.greenfacts.org. Retrieved 2018-12-19.
- Commonwealth of Australia. Department of Health and Ageing. National Industrial Chemicals Notification and Assessment Scheme. Priority Existing Chemical Assessment Report No. 30 Archived 2010-11-14 at the Wayback Machine. National Industrial Chemicals Notification and Assessment Scheme, Jan. 2009. Web. Apr. 2014.
- US Pharmacopoeia National Formulary. United States Pharmacopeial. 2012. ISBN 978-1936424122.
- Russell AD (May 2004). "Whither triclosan?". J. Antimicrob. Chemother. 53 (5): 693–95. doi:10.1093/jac/dkh171. PMID 15073159.
- The WHO Guidelines on Hand Hygiene in Healthcare (Advanced Draft), WHO, 2006, p. 37. "9.9 Triclosan"
- Witorsch RJ (2014). "Critical analysis of endocrine disruptive activity of triclosan and its relevance to human exposure through the use of personal care products". Crit. Rev. Toxicol. 44 (6): 535–55. doi:10.3109/10408444.2014.910754. PMID 24897554. S2CID 207505994.
- Witorsch RJ, Thomas JA (2010). "Personal care products and endocrine disruption: A critical review of the literature". Crit. Rev. Toxicol. 40 Suppl 3: 1–30. doi:10.3109/10408444.2010.515563. PMID 20932229. S2CID 4653232.
- Shrestha, Prabin; Ni, Jie; Wong, Tit-Yee (2020). "Synergistic and antagonistic interactions of triclosan with various antibiotics in bacteria". Journal of Environmental Science and Health, Part C. 38 (3): 187–203. doi:10.1080/26896583.2020.1781494. PMID 32648520.
- Shrestha, Prabin; Zhang, Yongmei; Chen, Wen-Jen; Wong, Tit-Yee (2020). "Triclosan: antimicrobial mechanisms, antibioticsinteractions, clinical applications, and human health". Journal of Environmental Science and Health, Part C. 38 (3): 245–268. doi:10.1080/26896583.2020.1809286. PMID 32955413.
- Halden, p. 3605.
- Mendez, Monica O.; Valdez, Erika M.; Martinez, Eileen M.; Saucedo, Melissa; Wilson, Brittan A. (2016). "Fate of Triclosan in Irrigated Soil: Degradation in Soil and Translocation into Onion and Tomato". Journal of Environmental Quality. 45 (3): 1029–35. doi:10.2134/jeq2015.07.0386. PMID 27136171.
- Izlar, Rossie. (May 25, 2016). Following Tricky Triclosan. Retrieved from American Society of Agronomy, https://www.agronomy.org/science-news/following-tricky-triclosan
- Yueh, Mei-Fei; Tukey, Robert H. (6 January 2016). "Triclosan: A Widespread Environmental Toxicant with Many Biological Effects". Annual Review of Pharmacology and Toxicology. 56 (1): 251–272. doi:10.1146/annurev-pharmtox-010715-103417. PMC 4774862. PMID 26738475.
- United States Geological Survey. Contaminants of Emerging Concern in the Environment. Retrieved October 27, 2016, from http://toxics.usgs.gov/investigations/cec/index.php
- Food and Drug Administration. (2016) 5 Things to know about Triclosan. Retrieved from https://www.fda.gov/forconsumers/consumerupdates/ucm205999.htm
- Food and Drug Administration (2016) FDA issues final rule on safety and effectiveness of antibacterial soaps. Available at: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm517478.htm
- Sicherer, Scott H.; Leung, Donald Y.M. (2013). "Advances in allergic skin disease, anaphylaxis, and hypersensitivity reactions to foods, drugs, and insects in 2012". Journal of Allergy and Clinical Immunology. 131 (1): 55–66. doi:10.1016/j.jaci.2012.11.007. PMID 23199604.
- Clayton, Erin M. Rees; Todd, Megan; Dowd, Jennifer Beam; Aiello, Allison E. (2010). "The Impact of Bisphenol a and Triclosan on Immune Parameters in the U.S. Population, NHANES 2003–2006". Environmental Health Perspectives. 119 (3): 390–96. doi:10.1289/ehp.1002883. PMC 3060004. PMID 21062687. Lay summary – ScienceDaily (Nov 30, 2010).
- Fulton, April (November 29, 2010). "New Questions Raised On Chemicals In Soaps, Plastics". NPR. Retrieved 2010-11-30.
- Bhutani, Tina; Jacob, Sharon E. (2009). "Triclosan". Dermatologic Surgery. 35 (5): 888–89. doi:10.1111/j.1524-4725.2009.01151.x. PMID 19389086.
- Campbell, Lauren; Zirwas, Matthew J.; Mowad, Christen M. (2006). "Triclosan". Dermatitis. 17 (4): 204–07. doi:10.2310/6620.2006.06014. PMID 17150172. S2CID 220577352.
- Bertelsen, R.J.; Longnecker, M.P.; Løvik, M.; Calafat, A.M.; Carlsen, K-H.; London, S.J.; Lødrup Carlsen, K.C. (2013). "Triclosan exposure and allergic sensitization in Norwegian children". Allergy. 68 (1): 84–91. doi:10.1111/all.12058. PMC 3515701. PMID 23146048.
- Bedoux, Gilles; Roig, Benoit; Thomas, Olivier; Dupont, Virginie; Le Bot, Barbara (2011). "Occurrence and toxicity of antimicrobial triclosan and by-products in the environment". Environmental Science and Pollution Research. 19 (4): 1044–65. doi:10.1007/s11356-011-0632-z. PMID 22057832. S2CID 35106807.
- "Triclosan Registration Review Preliminary Work Plan". Environmental Protection Agency. 27 March 2013.
- van den Berg, M; van Birgelen, A; Birnbaum, L; Brouwer, B; Carrier, G; Dragan, Y; Farland, W; Feeley, M; Fýrst, P; Galli, CL; Greig, J; Hayashi, Y; Kogevinas, M; Kurokawa, Y; Larsen, JC; Liem, AKD; Matsumura, F; Mocarelli, P; Moore, MR; Newhook, RC; Peterson, RE; Poellinger, L; Portier, C; Rogan, WJ; Schrenk, D; Sweeney, MH; Tohyama, C; Tuomisto, J; Water; Zeilmaker, M (2000). "Consultation on assessment of the health risk of dioxins; re-evaluation of the tolerable daily intake (TDI): Executive Summary". Food Additives and Contaminants. 17 (4): 223–40. doi:10.1080/713810655. PMID 10912238. S2CID 216644694.
- Stoker, Tammy E.; Gibson, Emily K.; Zorrilla, Leah M. (September 2010). "Triclosan Exposure Modulates Estrogen-Dependent Responses in the Female Wistar Rat". Toxicological Sciences. 117 (1): 45–53. doi:10.1093/toxsci/kfq180. PMID 20562219.
- Wang, Caifeng; Chen, Limei; Zhao, Shasha; Hu, Yi; Zhou, Yijun; Gao, Yu; Wang, Weiye; Zhang, Jun; Tian, Ying (February 2018). "Impacts of prenatal triclosan exposure on fetal reproductive hormones and its potential mechanism". Environment International. 111: 279–286. doi:10.1016/j.envint.2017.11.007. PMID 29150338.
- Halden, Rolf U (March 3, 2014). "On the need and speed of regulating triclosan and triclocarban in the United States". Environmental Science and Technology. 48 (7): 3603–11. Bibcode:2014EnST...48.3603H. doi:10.1021/es500495p. PMC 3974611. PMID 24588513.
- Kary, Tiffany (August 11, 2014). "Cancer-Linked Colgate Total Ingredient Suggests FDA Flaws". Bloomberg. Retrieved October 29, 2016. From embedded infographic: Triclosan: Four Decades of Regulatory Limbo
- "Company history", corporate website, Novartis, novartis.com, archived from the original on 30 December 2010
- "Homecare and I & I: Irgasan DP 300". BASF.com. Retrieved October 29, 2016.
- Halden, Rolf U. (2014). "On the Need and Speed of Regulating Triclosan and Triclocarban in the United States". Environmental Science & Technology. 48 (7): 3603–11. Bibcode:2014EnST...48.3603H. doi:10.1021/es500495p. PMC 3974611. PMID 24588513.
- Clarke, Bradley O.; Smith, Stephen R. (2011). "Review of 'emerging' organic contaminants in biosolids and assessment of international research priorities for the agricultural use of biosolids". Environment International. 37 (1): 226–47. doi:10.1016/j.envint.2010.06.004. PMID 20797791.
- "Triclosan Facts". Environmental Protection Agency. Retrieved 17 Feb 2014.
- Singer, Heinz; Müller, Stephan; Tixier, Céline; Pillonel, Laurent (2002). "Triclosan: Occurrence and Fate of a Widely Used Biocide in the Aquatic Environment: Field Measurements in Wastewater Treatment Plants, Surface Waters, and Lake Sediments". Environmental Science & Technology. 36 (23): 4998–5004. Bibcode:2002EnST...36.4998S. doi:10.1021/es025750i. PMID 12523412.
- Heidler, Jochen; Halden, Rolf U. (2007). "Mass balance assessment of triclosan removal during conventional sewage treatment". Chemosphere. 66 (2): 362–69. Bibcode:2007Chmsp..66..362H. doi:10.1016/j.chemosphere.2006.04.066. PMID 16766013.
- Stasinakis, Athanasios S.; Thomaidis, Nikolaos S.; Arvaniti, Olga S.; Asimakopoulos, Alexandros G.; Samaras, Vasilios G.; Ajibola, Akinranti; Mamais, Daniel; Lekkas, Themistokles D. (October 2013). "Contribution of primary and secondary treatment on the removal of benzothiazoles, benzotriazoles, endocrine disruptors, pharmaceuticals and perfluorinated compounds in a sewage treatment plant". Science of the Total Environment. 463–464: 1067–1075. Bibcode:2013ScTEn.463.1067S. doi:10.1016/j.scitotenv.2013.06.087. PMID 23891999.
- Dhillon, Gurpreet; Kaur, Surinder; Pulicharla, Rama; Brar, Satinder; Cledón, Maximiliano; Verma, Mausam; Surampalli, Rao (22 May 2015). "Triclosan: Current Status, Occurrence, Environmental Risks and Bioaccumulation Potential". International Journal of Environmental Research and Public Health. 12 (5): 5657–5684. doi:10.3390/ijerph120505657. PMC 4454990. PMID 26006133.
- Brausch, John; Rand, Gary (2011). "A review of personal care products in the aquatic environment: Environmental concentrations and toxicity". Chemosphere. 82 (11): 1518–32. Bibcode:2011Chmsp..82.1518B. doi:10.1016/j.chemosphere.2010.11.018. PMID 21185057.
- Hedrick-Hopper, Tiffany L.; Koster, Lauren P.; Diamond, Sandra L. (December 2015). "Accumulation of triclosan from diet and its neuroendocrine effects in Atlantic croaker (Micropogonias undulatus) under two temperature Regimes". Marine Environmental Research. 112 (Pt A): 52–60. doi:10.1016/j.marenvres.2015.09.006. PMID 26446583.
- "Estimates Of Exposures And Risks To Aquatic Organisms From Releases Of Triclosan To Surface Water As A Result Of Uses Under EPA'S Jurisdiction" (PDF). Retrieved 2014-09-22.
- Stasinakis, Athanasios S.; Mamais, Daniel; Thomaidis, Nikolaos S.; Danika, Elena; Gatidou, Georgia; Lekkas, Themistokles D. (June 2008). "Inhibitory effect of triclosan and nonylphenol on respiration rates and ammonia removal in activated sludge systems". Ecotoxicology and Environmental Safety. 70 (2): 199–206. doi:10.1016/j.ecoenv.2007.12.011. PMID 18237779.
- Thomaidi, Vasiliki S.; Matsoukas, Christos; Stasinakis, Athanasios S. (December 2017). "Risk assessment of triclosan released from sewage treatment plants in European rivers using a combination of risk quotient methodology and Monte Carlo simulation". Science of the Total Environment. 603–604: 487–494. Bibcode:2017ScTEn.603..487T. doi:10.1016/j.scitotenv.2017.06.113. PMID 28641188.
- Dann, Andrea B.; Hontela, Alice (May 2011). "Triclosan: environmental exposure, toxicity and mechanisms of action". Journal of Applied Toxicology. 31 (4): 285–311. doi:10.1002/jat.1660. PMID 21462230. S2CID 30753558.
- Shrestha, Prabin; Ni, Jie; Wong, Tit-Yee (2020). "Synergistic and antagonistic interactions of triclosan with various antibiotics in bacteria". Journal of Environmental Science and Health, Part C. 38 (3): 245–268. doi:10.1080/26896583.2020.1781494. PMID 32648520.
- Westgate, Rebecca; Grasha, Pierre; Maillard, Jean-Yves (2016). "Use of a predictive protocol to measure the antimicrobial resistance risks associated with biocidal product usage". American Journal of Infection Control. 44 (4): 458–64. doi:10.1016/j.ajic.2015.11.009. PMID 26810885.
- Aiello, A.E.; Larson, E.L.; Levy, S.B. (2007). "Consumer Antibacterial Soaps: Effective or Just Risky?" (PDF). Clinical Infectious Diseases. 45: S137–47. doi:10.1086/519255. PMID 17683018. Lay summary – Phys.org (Aug 15, 2007).
- Kim, Jun Sung; Kuk, Eunye; Yu, Kyeong Nam; Kim, Jong-Ho; Park, Sung Jin; Lee, Hu Jang; Kim, So Hyun; Park, Young Kyung; Park, Yong Ho; Hwang, Cheol-Yong; Kim, Yong-Kwon; Lee, Yoon-Sik; Jeong, Dae Hong; Cho, Myung-Haing (2007). "Antimicrobial effects of silver nanoparticles". Nanomedicine: Nanotechnology, Biology and Medicine. 3 (1): S137–47. doi:10.1016/j.nano.2006.12.001. hdl:10371/8335. PMID 17379174.
- Proposal to Establish a Monograph for OTC Topical Antimicrobial Products. Federal Register, vol. 39, no. 179. September 13, 1974. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/UCM107140.pdf
- Topical Antimicrobial Products for Over-the-Counter Human Use: Reopening of the Administrative Record. Federal Register, vol. 44, no. 48. March 9, 1979. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/UCM107157.pdf
- Topical Antimicrobial Drug Products for Over-the-Counter Human Use. Federal Register, vol. 59, no. 116. June 17, 1994. https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-CounterOTCDrugs/StatusofOTCRulemakings/UCM110451.pdf
- Halden, p. 3606, figure 1.
- "Federal Register" (PDF). Retrieved 2014-09-22.
- Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use. Federal Register, vol. 81, no. 172. September 6, 2016. https://www.gpo.gov/fdsys/pkg/FR-2016-09-06/pdf/2016-21337.pdf
- Landau, Elizabeth and Young, Saundra. (May 21, 2014). Minnesota issues ban on antibacterial ingredient. CNN. Retrieved from http://www.cnn.com/2014/05/21/health/triclosan-ban-antibacterial/
- Purtill, Corinne (February 2, 2019). "Colgate eliminated triclosan from its toothpaste. Could a ban be on the way?". Quartz. Retrieved June 26, 2019.
- Kary, Tiffany. Triclosan: Four Decades of Regulatory Limbo. (August 11, 2014). [Infographic embedded in article Cancer-Linked Colgate Total Ingredient Suggests FDA flaws]. Bloomberg. Retrieved from https://www.bloomberg.com/graphics/infographics/triclosan-four-decades-of-regulatory-limbo.html
- Weeks, Carly. (Sept 6 2016). The FDA will ban antibacterial ingredients from soaps. What about Canada? The Globe and Mail. Retrieved from https://www.theglobeandmail.com/life/health-and-fitness/health/the-fda-will-ban-antibacterial-ingredients-from-soaps-what-about-canada/article31729886/
- Consumer Ingredient Hotlist. Health Canada website. Retrieved October 20, 2016, http://www.hc-sc.gc.ca/cps-spc/cosmet-person/hot-list-critique/hotlist-liste-eng.php
- "EUR-Lex – 32016D0110 – EN – EUR-Lex". eur-lex.europa.eu. Retrieved 8 September 2017.
- "REGULATION (EC) No 1223 /2009 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 30 November 2009 on cosmetic products". Official Journal of the European Union. 2009.
- Commission Regulation (EU) No 358/2014 of 9 April 2014